

## Technology Advisory Committee C Interests Register

**Topic: Molnupiravir for treating COVID-19 [ID6340]**

**Publication Date: 16 April 2025**

| Name              | Role with NICE       | Type of interest  | Description of interest   | Interest declared        | Comments  |
|-------------------|----------------------|-------------------|---|--------------------------|---|
| Michael Chambers  | TAC Committee Member | Direct- financial | Michael has participated in an advisory panel for Pfizer in an unrelated disease area, prostate cancer.   | 11/10/2024<br>11/02/2025 | It was agreed that Michael's declaration would not prevent him from participating in discussions on this appraisal.   |
| Dr Kate Ren       | TAC Committee Member | Non-financial     | Kate was a member of the EAG which conducted the MTA for Covid-19 treatments. She also provided statistical methodology consultancy service for a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis). | 12/10/2024<br>11/02/2025 | It was agreed that Kate's declaration would not prevent her from participating in discussions on this appraisal.      |
| Elizabeth Thurgar | TAC Committee Member | Direct- financial | In the past 12 months, Elizabeth has provided consultancy advice to Kite, owned by Gilead Sciences, a listed comparator company, in an unrelated condition: mantle cell lymphoma. Elizabeth currently works   | 14/10/2024<br>11/02/2025 | It was agreed that Elizabeth's declaration would not prevent her from participating in discussions on this appraisal. |

| Name              | Role with NICE       | Type of interest  | Description of interest   | Interest declared        | Comments  |
|-------------------|----------------------|-------------------|---|--------------------------|---|
|                   |                      |                   | with Pfizer, a listed comparator company, in an unrelated indication, non-small cell lung cancer.   |                          |   |
| Dr Prithwiraj Das | TAC Committee Member | Non-financial     | Prithwiraj, is currently engaged in helping one of the comparator manufacturers, GSK on an unrelated indication.  | 23/01/2025               |   |
| David Lowe        | Clinical Expert      | Direct- financial | David is a member of the NHS England National Expert Working Group for COVID-19 therapeutics, the Independent Advisory Group on highest risk subgroups for COVID-19 and the European Society for Immunodeficiencies Clinical Working Party COVID-19 group. He was the Chief Investigator of the FLARE trial investigating early oral antivirals for COVID-19 (2020-2021). He is an Investigator, co-applicant and lead for Virology substudies of the PANORAMIC trial investigating early oral antivirals for COVID-19, including molnupiravir. He has published in multiple publications on viral infection and antivirals. His institution, UCL, has received | 26/09/2024<br>11/02/2025 | It was agreed that David's declaration would not prevent him from providing expert advice to the committee. |

| Name          | Role with NICE  | Type of interest  | Description of interest  | Interest declared        | Comments  |
|---------------|-----------------|-------------------|--|--------------------------|---|
|               |                 |                   | research grants from GSK, a comparator company. David's spouse is employed by GSK, a comparator company. His nominating organisation, the British Society for Immunology, has received funding from MSD. |                          |   |
| Brendan Payne | Clinical Expert | Direct- financial | Brendan is the principal investigator for a current MSD sponsored clinical trial which is running at his site. It is not in this clinical disease area.  | 14/06/2024               | It was agreed that Brendan's declaration would not prevent him from providing expert advice to the committee. |
| Robert Burns  | Clinical Expert | Direct- financial | Robert holds shares in GSK, a comparator company.  | 02/10/2024<br>11/02/2025 | It was agreed that Robert's declaration would not prevent him from providing expert advice to the committee.  |